021-51111890
购物车（）
sales@molnova.cn
MI-136
CAS No. 1628316-74-4
MI-136 ( MI 136 | MI136 )
产品货号. M12427 CAS No. 1628316-74-4
一种有效的 Menin-MLL 相互作用抑制剂，IC50 为 31 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥462 | 有现货 |
|
| 5MG | ￥721 | 有现货 |
|
| 10MG | ￥1215 | 有现货 |
|
| 25MG | ￥2373 | 有现货 |
|
| 50MG | ￥4301 | 有现货 |
|
| 100MG | ￥6221 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称MI-136
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种有效的 Menin-MLL 相互作用抑制剂，IC50 为 31 nM。
-
产品描述A potent Menin-MLL interaction inhibitor with IC50 of 31 nM; demonstrates potent inhibitory activity and strong binding affinity to menin.
-
体外实验MI-136 (0-20) exhibits IC50values of 5.59 μM, 7.15 μM, 5.37 μM and 19.76 μM in LNCaP, VCaP, 22rv1 and PNT2 cells.Cell Proliferation Assay Cell Line:AR positive cell lines such as VCaP, LNCaP and 22RV1.Concentration:0-20 μM.Incubation Time:24 h.Result:Inhibited cell proliferation.
-
体内实验MI-136 exhibits T1/2 of 3.1 h after po administration.MI-136 (40 mg/kg, ip) leads to a significant decrease in the growth of castration-resistant VCaP tumors. Animal Model:VCaP xenografts.Dosage:40 mg/kg.Administration:Intraperitoneal injection, 5 days a week.Result:Led to a significant decrease in the growth of castration-resistant VCaP tumors compared to vehicle controls.
-
同义词MI 136 | MI136
-
通路Chromatin/Epigenetic
-
靶点HMTase
-
受体AndrogenReceptor
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1628316-74-4
-
分子量470.5132
-
分子式C23H21F3N6S
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 31 mg/mL
-
SMILESC1CN(CCC1NC2=C3C=C(SC3=NC=N2)CC(F)(F)F)CC4=CC5=C(C=C4)NC(=C5)C#N
-
化学全称1H-Indole-2-carbonitrile, 5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Borkin D, et al. J Med Chem. 2016 Feb 11;59(3):892-913.
2. Borkin D, et al. Cancer Cell. 2015 Apr 13;27(4):589-602.
